Swiss National Bank lifted its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 266,300 shares of the biopharmaceutical company’s stock after purchasing an additional 6,800 shares during the quarter. Swiss National Bank’s holdings in Nektar Therapeutics were worth $15,903,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. California Public Employees Retirement System raised its position in Nektar Therapeutics by 19.6% in the fourth quarter. California Public Employees Retirement System now owns 233,379 shares of the biopharmaceutical company’s stock worth $13,937,000 after acquiring an additional 38,179 shares in the last quarter. Teacher Retirement System of Texas raised its position in Nektar Therapeutics by 322.7% in the fourth quarter. Teacher Retirement System of Texas now owns 53,545 shares of the biopharmaceutical company’s stock worth $3,198,000 after acquiring an additional 40,879 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in Nektar Therapeutics by 2.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 30,168 shares of the biopharmaceutical company’s stock worth $1,802,000 after acquiring an additional 829 shares in the last quarter. First Mercantile Trust Co. acquired a new stake in Nektar Therapeutics during the 4th quarter worth about $298,000. Finally, Meeder Asset Management Inc. acquired a new stake in Nektar Therapeutics during the 4th quarter worth about $121,000. Institutional investors and hedge funds own 96.23% of the company’s stock.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at $83.43 on Tuesday. Nektar Therapeutics has a 1-year low of $12.50 and a 1-year high of $99.02. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. The firm has a market capitalization of $13,140.00, a P/E ratio of -117.51 and a beta of 2.04.
In other news, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the completion of the transaction, the chief executive officer now directly owns 272,768 shares in the company, valued at $15,190,449.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher A. Kuebler sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total value of $1,759,800.00. Following the transaction, the director now owns 70,500 shares of the company’s stock, valued at $4,135,530. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 196,666 shares of company stock valued at $12,718,923. Corporate insiders own 5.44% of the company’s stock.
WARNING: “Nektar Therapeutics (NKTR) Position Raised by Swiss National Bank” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2018/02/20/nektar-therapeutics-nktr-position-raised-by-swiss-national-bank.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.